

Behind KANJINTI is the experience your patients can trust

**NOW
AVAILABLE IN
SAUDI ARABIA**

Introducing KANJINTI from Amgen, the first and only trastuzumab biosimilar with single-switch data in the curative setting.²

KANJINTI
(trastuzumab)



THE FIRST AND ONLY Trastuzumab biosimilar with single-transition study data in the **eBC** SETTINGS¹⁻⁸

IDENTICAL DOSING
to the Reference Product IV

AVAILABLE IN A MULTI-DOSE*
420 MG VIAL^{1,9}

**BACKED BY AMGEN
EXPERTISE**

40
YEARS
experience in biologics¹⁰

- ✓ FDA and EMA Approved^{1,9}
- ✓ Included in NCCN Guidelines¹¹
- ✓ Has Comprehensive Totality of Evidence¹²
- ✓ Approved Extrapolation for all Indications^{1,9}



INDICATIONS¹

KANJINTI[®] is a trastuzumab indicated for the treatment of HER2-positive metastatic breast cancer, HER2-positive early breast cancer and HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction.¹

HER2= human epidermal growth factor receptor 2.

*Multi-dose when reconstituted with Bacteriostatic Water for Injection.

References

1. KANJINTI (trastuzumab-anns) Prescribing information, Amgen, last revised in September 2018. 2. von Minckwitz G, Colleoni M, Kolberg HC, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. *Lancet Oncol.* 2018;19:987-998. 3. Nixon N, Hannouf M, Verna S. The evolution of biosimilars in oncology, with a focus on trastuzumab. *Curr Oncol.* 2018;25:S171-S179. 4. Pegram MD, Bondarenko I, Zorzetto MMC, et al. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind. *Br J Cancer.* 2019;120:172-182. 5. Pivov X, Bondarenko I, Nowecki Z, et al. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. *J Clin Oncol.* 2018;36:968-974. 6. Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. *Lancet Oncol.* 2017;18:917-928. 7. Chen X, Li C, Ewesudeo R, Yin D. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin[®]) in patients with HER2-positive metastatic breast cancer. *Cancer Chemother Pharmacol.* 2019;84:83-92. doi:10.1007/s00280-019-03850-1 [Epub ahead of print]. 8. Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomised clinical trial. *JAMA.* 2017;317:37-47. 9. Herceptin[®] (trastuzumab) Prescribing information, Genentech, USA. 10. Data on file, Amgen. 11. The NCCN[®] Clinical Practice Guidelines in Oncology, National Comprehensive Cancer website. www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed September 30, 2019. 12. US Food and Drug Administration Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. www.fda.gov/downloads/drugs/guidances/ucm291128.pdf. Accessed September 30, 2019.

API (November 2019) will be provided upon request

AMGEN

Amgen GmbH Limited
PO. BOX 7561, Riyadh, Al Olaya
Office 1102
Centeria Mall - 4th floor
Riyadah 12242
Saudi Arabia

PR-KAN-SAU-00014-08-2021